2 assets in Agammaglobulinemia

Therapeutic assets addressing Agammaglobulinemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
20-valent pneumococcal conjugate vaccine Agammaglobulinemia	University of Alabama at Birmingham	P4	BB (65)
Human Immune Globulin G Agammaglobulinemia	Rutgers, The State University of New Jersey	P1	NR ()